Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$8.50
-0.1%
C$8.12
C$3.11
C$9.98
C$203.92M0.9740,007 shs19,724 shs
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
C$0.11
-12.0%
C$0.11
C$0.11
C$4.00
C$719KN/A12,163 shs21,587 shs
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$7.63
-5.1%
$10.03
$7.61
$27.48
$1.03B0.411.04 million shs901,238 shs
Zomedica Corp. stock logo
ZOM
Zomedica
$0.13
$0.00
$0.12
$0.25
$127.49M15.17 million shs1.36 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
-3.41%-3.51%-8.89%+49.04%+152.52%
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
0.00%0.00%0.00%0.00%0.00%
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-1.11%-2.55%-19.60%-17.11%-67.76%
Zomedica Corp. stock logo
ZOM
Zomedica
-7.20%-7.20%-5.65%-3.27%-38.50%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
N/AN/AN/AN/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.1474 of 5 stars
3.31.00.00.01.43.31.3
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
3.00
BuyC$8.00-5.88% Downside
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
N/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
2.57
Moderate Buy$34.38350.52% Upside
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/A

Current Analyst Ratings

Latest VIR, VLG, ZOM, CPH, and SUGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$110.00
2/23/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$9.00 ➝ $10.00
2/14/2024
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSpeculative Buy ➝ BuyC$4.75 ➝ C$8.00
2/14/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$85.00 ➝ $110.00
1/29/2024
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$23.00 ➝ $9.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$21.16M9.64C$2.41 per share3.53C$3.36 per share2.53
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
C$2.24M0.32C$0.00 per share110.00C$11.57 per share0.01
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
$86.18M11.91N/AN/A$11.82 per share0.65
Zomedica Corp. stock logo
ZOM
Zomedica
$25.19M5.06N/AN/A$0.24 per share0.54

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$20.38MC$1.097.80N/A96.32%28.19%8.06%5/9/2024 (Estimated)
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
N/AC$0.720.15N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$615.06M-$4.59N/AN/AN/A-713.69%-34.92%-27.73%5/2/2024 (Confirmed)
Zomedica Corp. stock logo
ZOM
Zomedica
-$34.53M-$0.04N/AN/A-137.10%-8.13%-7.68%5/9/2024 (Estimated)

Latest VIR, VLG, ZOM, CPH, and SUGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$0.99N/A+$0.99N/AN/AN/A  
4/1/2024Q4 2023
Zomedica Corp. stock logo
ZOM
Zomedica
N/A-$0.01-$0.01N/A$7.00 million$7.34 million    
3/14/2024Q4 2023
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
C$0.15C$0.41+C$0.26C$0.41C$7.31 millionC$6.70 million
2/22/2024Q4 2023
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
-$1.14-$0.86+$0.28-$0.86$11.18 million$16.80 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
N/AN/AN/AN/AN/A
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
N/AN/AN/AN/AN/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/AN/AN/AN/AN/A
Zomedica Corp. stock logo
ZOM
Zomedica
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
0.44
9.19
2.67
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
142.67
0.46
0.03
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
N/A
9.05
9.05
Zomedica Corp. stock logo
ZOM
Zomedica
N/A
11.06
10.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
1.03%
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
65.32%
Zomedica Corp. stock logo
ZOM
Zomedica
8.95%

Insider Ownership

CompanyInsider Ownership
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
44.73%
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
N/A
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
18.10%
Zomedica Corp. stock logo
ZOM
Zomedica
4.18%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cipher Pharmaceuticals Inc. stock logo
CPH
Cipher Pharmaceuticals
523.99 millionN/ANot Optionable
SugarBud Craft Growers Corp. stock logo
SUGR
SugarBud Craft Growers
446.53 millionN/ANot Optionable
Vir Biotechnology, Inc. stock logo
VIR
Vir Biotechnology
587134.50 million110.16 millionOptionable
Zomedica Corp. stock logo
ZOM
Zomedica
144979.95 million938.99 millionNot Optionable

VIR, VLG, ZOM, CPH, and SUGR Headlines

SourceHeadline
What’s Happening at the Defender Kentucky Three Day EventWhat’s Happening at the Defender Kentucky Three Day Event
eventingnation.com - April 21 at 12:53 PM
Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%Zomedica (NYSEAMERICAN:ZOM) Stock Price Down 4.3%
americanbankingnews.com - April 21 at 6:12 AM
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
accesswire.com - April 9 at 6:30 AM
Zomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call TranscriptZomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcript
msn.com - April 2 at 4:06 PM
Q4 2023 Zomedica Corp Earnings CallQ4 2023 Zomedica Corp Earnings Call
finance.yahoo.com - April 2 at 8:30 AM
ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023ZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023
investorplace.com - April 1 at 9:06 PM
Zomedica reports Q4 resultsZomedica reports Q4 results
msn.com - April 1 at 5:27 PM
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in LiquidityZomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
accesswire.com - April 1 at 4:05 PM
The Next Millionaire-Makers: 3 Penny Stocks With Massive Upside PotentialThe Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potential
investorplace.com - April 1 at 3:12 PM
Zomedica to Report Fourth Quarter and Full Year 20…Zomedica to Report Fourth Quarter and Full Year 20…
pharmiweb.com - March 20 at 9:17 AM
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
accesswire.com - March 20 at 6:30 AM
Zomedica Pharmaceuticals Corp (ZOM)Zomedica Pharmaceuticals Corp (ZOM)
investing.com - March 15 at 7:52 AM
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) PlatformZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
accesswire.com - March 14 at 6:30 AM
Zomedica Provides NYSE American Listing UpdateZomedica Provides NYSE American Listing Update
accesswire.com - March 13 at 4:45 PM
Sidoti & Company, LLC: Sidoti Events, LLCs Virtual March Small-Cap ConferenceSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conference
finanznachrichten.de - March 12 at 11:26 AM
Zomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary ConferencesZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
finanznachrichten.de - March 12 at 8:22 AM
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary ConferencesZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
accesswire.com - March 12 at 6:30 AM
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working DogsZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
accesswire.com - March 7 at 6:30 AM
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
accesswire.com - March 5 at 6:30 AM
Zomedica Pharmaceuticals Corp. (ZOM)Zomedica Pharmaceuticals Corp. (ZOM)
uk.finance.yahoo.com - March 1 at 2:46 PM
Zomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health ConferencesZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
finanznachrichten.de - February 8 at 9:14 AM
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health ConferencesZomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
finance.yahoo.com - February 8 at 9:14 AM
Zomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share ConsolidationZomedica Corp.: Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation
finanznachrichten.de - February 6 at 5:00 PM
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)
finance.yahoo.com - February 6 at 5:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Cipher Pharmaceuticals logo

Cipher Pharmaceuticals

TSE:CPH
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.
SugarBud Craft Growers logo

SugarBud Craft Growers

CVE:SUGR
SugarBud Craft Growers Corp. engages in the development, production, distribution, and sale of cannabis products in Canada. It offers cannabis extract, edible, and topical products through distributors and retailers, as well as to registered medical patients through CannMart.com. The company was formerly known as Relentless Resources Ltd. and changed its name to SugarBud Craft Growers Corp. in October 2018. SugarBud Craft Growers Corp. is headquartered in Calgary, Canada.
Vir Biotechnology logo

Vir Biotechnology

NASDAQ:VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Zomedica logo

Zomedica

NYSEAMERICAN:ZOM
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.